

**Photocatalyst-Free Visible-Light Triggered Amination of
Benzo[c][1,2,5]thiadiazole: Direct C–N Bond Formation from
C(sp²)–H bond**

Contents:


1. General	S2
2. Synthesis of benzo[c][1,2,5]thiadiazole	S3
3. Optimization survey	S4
4. Experimental procedure for the synthesis of 3a-3v	S6
5. Spectroscopic data of 3a-3v	S7
6. References.	S19
7. Copies of ¹ H and ¹³ C NMR spectra of 3a to 3v	S20

1. General

All the reactions were performed using oven-dried standard glassware or screw-caped vials. The reactions are stirred magnetically and monitored by analytical thin layer chromatography (TLC). TLC was made by silica gel 60 F254, and UV lamp was used as visualizing agent. Iodine, 5% aqueous potassium permanganate solutions were used as a developing agents followed by heating. Purification of products was performed using column chromatography on silica gel (100–120 and 230–400, mesh) where it is required. hexane/ethyl acetate was used as eluents. The solvents were removed by rotary evaporator at 40–45 °C under reduced pressure. All the reagents and solvents were purchased from commercial suppliers. Melting points reported in this work are uncorrected. ^1H NMR spectra were recorded on 300, 400, and 500 MHz instruments. Chemical shifts (δ) are reported in parts per million (ppm) with the reference solvent and the internal standards (TMS = 0; CDCl_3 = 7.26).^[1] The following abbreviations were used to explain the multiplicity of the spectra (s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, sep = septet, and m = multiplet). ^{13}C NMR spectra were recorded on 75, 100, and 125 MHz spectrometers. Infrared spectroscopy was performed neat on a BRUKER FT-IR spectrophotometer in chloroform; IR[KBr] spectra were recorded on a Thermo Nicolet-NEXUS 670 FT-IR instrument. Mass spectrometric analyses were performed using ESI techniques, mass spectra obtained on a SHIMADZU LCMS-2020 mass spectrometer. High Resolution Mass Spectra data were obtained on a Thermo scientific ExactiveTMOrbitrap mass spectrometer or Q STAR XL Hybrid MS/MS.

2. Synthesis of Benzo[c][1,2,5]thiadiazole derivatives

In a clean round bottom flask, 1, 2-diaminobenzene derivative (30.05 mmol) were taken and dissolved in CH_2Cl_2 (20 mL) followed by the addition of triethylamine (130.0 mmol). In an addition funnel, 96.0 mmol of SOCl_2 was dissolved in CH_2Cl_2 (10 mL) and added drop wise to the reaction mixture, stir the reaction mixture at reflux temperature. Reaction was monitored by TLC. After completion of reaction, removed the solvent under vacuum, the combined organic layer was washed with water and concentrated under vacuum. The benzo[c][1,2,5]thiadiazole derivatives were isolated by column chromatography. The synthesized benzothiadiazole derivatives are good agreement with literature reports.^[2]



3. Optimization survey

In a clean, oven dried reaction vial, chlorine source (1 equiv.) and benzo[c][1,2,5]thiadiazole (1 mmol) was taken and closes the vial with a rubber septa and apply degassing with nitrogen gas. Under nitrogen solvent was added followed by the addition of piperidine (0.5 mmol). Stir the reaction mixture at ambient temperatures for 30 mints and then add 2 equivalents of acidic source, stir the reaction mixture under blue LED at ambient temperatures until the indicated reaction time. Reaction was monitoring by TLC. After reaction completion, the reaction mixture was diluted with ethyl acetate (3 x 10 mL) and 1 N of KOH solution (10 mL). The organic layer was taken and dried over anhydrous Na_2SO_4 then concentration under vacuum. The 4-(piperidin-1-yl)benzo[c][1,2,5]thiadiazole was collected by column chromatography.





Table 1: Optimization survey

S. No	Chlorine source	Acid	Solvent	T (h)	Yield of 3 ^b
1	NCS	HClO ₄	CH ₃ CN	1	-
2	NCS	HClO ₄	CH ₃ CN	2	-
3	NCS	HClO ₄	CH ₃ CN	4	-
4	NCS	HClO ₄	CH ₃ CN	6	8
5	NCS	HClO ₄	CH ₃ CN	12	22
6	NCS	HClO ₄	CH ₃ CN	24	62
7	Cyanuric chloride	HClO ₄	CH ₃ CN	24	-
8	Trichloroisocyanuric acid	HClO ₄	CH ₃ CN	24	-
9	NCS	HCl	CH ₃ CN	24	-
10	NCS	H₂SO₄	CH ₃ CN	24	-
11	NCS	HNO₃	CH ₃ CN	24	-
12	NCS	MSA	CH ₃ CN	24	19
13	NCS	Pivalic acid	CH ₃ CN	24	-
14	NCS	HClO ₄	HFIP	24	78
15	NCS	HClO ₄	C₂H₅OH	24	-
16	NCS	HClO ₄	DMSO	24	-
17	NCS	HClO ₄	DMF	24	-
18	NCS	HClO ₄	Toluene	24	-
19	NCS	HClO ₄	DCE	24	-
20	-	HClO ₄	HFIP	24	-
21	NCS	-	HFIP	24	-
22 ^c	NCS	HClO ₄	HFIP	24	-

^aReaction conditions: **1** (1 mmol), **2a** (0.5 mmol), chlorine source (1 equiv.), Acid (2 equiv.), solvent (2 mL), at ambient temperature; ^bYields are of isolated products; ^cReaction carried in the absence of light; CC = Cyanuric chloride; TIC = Trichloroisocyanuric acid.


4. Experimental procedure for the synthesis of 3a-3v

In a clean, oven dried reaction vial, chlorine source (1 equiv., 0.5 mmol) and benzothiadiazole derivatives (2 equiv., 1 mmol) was taken and closes the vial with a rubber septa and apply degassing with nitrogen gas. Under nitrogen HFIP (2 mL) was added followed by the addition of piperidine (1 equiv., 0.5 mmol). Stir the reaction mixture at ambient temperatures for 30 mints and then add 2 equivalents of HClO_4 , stir the reaction mixture under blue LED at ambient temperatures until the indicated reaction time. Reaction was monitoring by TLC. After reaction completion, the reaction mixture was diluted with ethyl acetate (3×10 mL) and 1 N of KOH solution (10 mL). The organic layer was taken and dried over anhydrous Na_2SO_4 then concentration under vacuum. The aminatedbenzothiadiazoles **3a-3v** was collected by column chromatography.




5. Spectroscopic data of 3a-3v

4-(piperidin-1-yl)benzo[c][1,2,5]thiadiazole (3a)




Yellow solid, 85 mg, 78%, $R_f = 0.45$ (EtOAC/Hexane, 05:95); **MP** 148–150°C; **IR** (KBr) 666, 1464, 1518, 1639, 1689, 2860, 2927, 2860, 2927 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 1.55–1.62 (m, 2H), 1.76 (dt, $J = 11.3, 5.8$ Hz, 4H), 3.35–3.41 (m, 4H), 6.63 (d, $J = 7.1$ Hz, 1H), 7.32–7.44 (m, 2H); **$^{13}\text{C NMR}$** (101 MHz, CDCl_3) δ 24.6, 25.9, 51.7, 111.4, 112.9, 130.6, 145.3, 150.0, 156.7; **MS** (ESI) m/z 220 [M+H]⁺, **HRMS** (ESI, m/z): calcd for $\text{C}_{11}\text{H}_{14}\text{N}_3\text{S}$ [M+H]⁺ 220.10287, found 220.10172.

1-(benzo[c][1,2,5]thiadiazol-4-yl)piperidin-4-ol (3b)




Yellow solid, 96 mg, 82%, $R_f = 0.48$ (EtOAC/Hexane, 1:1); **MP** 154–156°C; **IR** (KBr) 627, 900, 1133, 1298, 1573, 2870, 2943 cm^{-1} ; **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 1.79 (m, 2H), 2.07 (d, $J = 9.6$ Hz, 2H), 3.13 (m, $J = 12.4$ Hz, 2H), 3.87–3.94 (m, 3H), 6.69 (d, $J = 6.5$ Hz, 1H), 7.39 (dd, $J = 8.7, 7.3$ Hz, 1H), 7.46 (d, $J = 8.6$ Hz, 1H); **$^{13}\text{C NMR}$** (101 MHz, CDCl_3) δ 34.4, 40.5, 48.0, 67.8, 111.7, 113.4, 130.5, 144.4, 149.8, 156.7; **MS** (ESI) m/z 236 [M+H]⁺, **HRMS** (ESI, m/z): calcd for $\text{C}_{11}\text{H}_{14}\text{N}_3\text{OS}$ [M+H]⁺ 236.08576, found 236.08500.

1-(benzo[*c*][1,2,5]thiadiazol-4-yl)piperidin-3-ol (3c)




Yellow solid, 94 mg, 80%, $\mathbf{R}_f = 0.52$ (EtOAC/Hexane, 1:1); **MP** 151–153°C; **IR** (KBr) 658, 1094, 1260, 1382, 1460, 1541, 2862, 2928 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 1.78 (dt, *J* = 13.2, 6.4 Hz, 2H), 1.87–1.93 (m, 1H), 2.07 (d, *J* = 4.9 Hz, 1H), 3.33 (d, *J* = 5.5 Hz, 1H), 3.40–3.47 (m, 1H), 3.53 (s, 1H), 3.60 (dd, *J* = 11.8, 2.7 Hz, 1H), 4.10 (s, 1H), 6.75 (d, *J* = 7.2 Hz, 1H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 8.7 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 22.0, 32.1, 50.7, 57.7, 66.4, 112.2, 113.6, 130.5, 144.8, 149.9, 156.6; **MS** (ESI) m/z 236 [M+H]⁺ **HRMS** (ESI, m/z): calcd for C₁₁H₁₄N₃OS [M+H]⁺ 236.08576, found 236.08479.

4-(4-methylpiperidin-1-yl)benzo[*c*][1,2,5]thiadiazole (3d)




Yellow solid, 85 mg, 73%, $\mathbf{R}_f = 0.45$ (EtOAC/Hexane, 05:95); **MP** 144–146°C; **IR** (KBr) 810, 1101, 1264, 1460, 2850, 2928 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 1.04 (d, *J* = 6.2 Hz, 3H), 1.47–1.61 (m, 3H), 1.83 (dd, *J* = 12.7, 1.6 Hz, 2H), 2.84 (dd, *J* = 17.2, 7.0 Hz, 2H), 4.17 (d, *J* = 12.3 Hz, 2H), 6.73 (d, *J* = 7.3 Hz, 1H), 7.47 (dt, *J* = 8.7, 8.1 Hz, 2H); **¹³C NMR** (101 MHz, CDCl₃) δ 21.9, 31.0, 34.3, 51.0, 111.5, 112.9, 130.5, 145.2, 150.0, 156.7; **MS** (ESI) m/z 234 [M+H]⁺ **HRMS** (ESI, m/z): calcd for C₁₂H₁₆N₃S [M+H]⁺ 234.10649, found 234.234.10624.

4-(2-methylpiperidin-1-yl)benzo[*c*][1,2,5]thiadiazole (3e)




Yellow solid, 77 mg, 66%, $R_f = 0.46$ (EtOAc/Hexane, 05:95); **MP** 162–164°C; **IR** (KBr) 2928, 2860, 1564, 1420, 1223, 1084, 629 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 0.97 (d, *J* = 6.8 Hz, 3H), 1.71 (m, 4H), 1.97–2.07 (m, 1H), 3.19–3.26 (m, 1H), 3.30–3.36 (m, 1H), 4.83–4.91 (m, 1H), 6.64 (d, *J* = 6.5 Hz, 1H), 7.40 (d, *J* = 8.7, 4.1 Hz, 2H); **¹³C NMR** (101 MHz, CDCl₃) δ 13.8, 19.3, 26.1, 31.2, 45.1, 51.7, 112.7, 113.0, 130.6, 144.6, 150.2, 156.8; **MS** (ESI) m/z 234 [M+H]⁺; **HRMS** (ESI, m/z): calcd for C₁₂H₁₆N₃S [M+H]⁺ 234.11852, found 234.11747.

4-(pyrrolidin-1-yl)benzo[*c*][1,2,5]thiadiazole (3f)




Yellow solid, 83 mg, 81%, $R_f = 0.42$ (EtOAC/Hexane, 05:95); **MP** 145–147°C; **IR** (KBr) 1100, 1223, 1261, 1714, 2866, 2944 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 2.06 (dd, *J* = 6.3, 3.3 Hz, 4H), 3.84 (dd, *J* = 7.9, 5.4 Hz, 4H), 6.24 (d, *J* = 7.6 Hz, 1H), 7.21 (d, *J* = 8.5 Hz, 1H), 7.42 (dd, *J* = 8.6, 7.7 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 35.2, 51.8, 117.2, 127.4, 133.2, 141.9, 158.9, 160.9. **MS** (ESI) m/z 206 [M+H]⁺; **HRMS** (ESI, m/z): calcd for C₁₀H₁₂N₃S [M+H]⁺ 206.07519, found 206.07491.

4-(azetidin-1-yl)benzo[*c*][1,2,5]thiadiazole (3g)




Yellow solid, 82 mg, 86%, $R_f = 0.44$ (EtOAC/Hexane, 05:95); **MP** 138–140°C; **IR** (KBr) 740, 1306, 1493, 1547, 2865, 2927 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 2.39–2.52 (m, 2H), 4.33 (t, *J* = 7.3 Hz, 4H), 6.14 (d, *J* = 7.4 Hz, 1H), 7.26 (t, *J* = 4.1 Hz, 1H), 7.41 (dd, *J* = 8.7, 7.4 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 17.6, 54.1, 103.6, 108.9, 130.7, 143.4, 147.7, 156.7; **MS** (ESI) m/z 192 [M+H]⁺; **HRMS** (ESI, m/z): calcd for C₉H₁₀N₃S [M+H]⁺ 192.05954, found 192.05864.

***N,N*-dimethylbenzo[*c*][1,2,5]thiadiazol-4-amine (3h)**




Yellow liquid, 71 mg, 75%, $R_f = 0.6$ (EtOAC/Hexane, 05:95); **IR** (KBr) 662, 1223, 1420, 1537, 2958, 2868 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 3.20 (s, 6H), 6.48 (dd, *J* = 6.8, 1.6 Hz, 1H), 7.33–7.41 (m, 2H); **¹³C NMR** (101 MHz, CDCl₃) δ 42.6, 108.9, 111.1, 130.8, 144.5, 149.3, 156.9; **MS** (ESI) m/z 180 [M+H]⁺

1-(6-methylbenzo[*c*][1,2,5]thiadiazol-4-yl)piperidin-4-ol (3i)




Yellow solid, 98 mg, 79%, R_f = 0.47 (EtOAC/Hexane, 1:1); **MP** 168–170°C; **IR** (KBr) 625, 1074, 1292, 1375, 1462, 2859, 2927 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 1.75–1.85 (m, 3H), 2.05 (t, *J* = 12.6 Hz, 3H), 2.39 (d, *J* = 1.0 Hz, 4H), 3.05–3.14 (m, 3H), 3.89 (dd, *J* = 8.5, 4.2 Hz, 4H), 6.52 (s, 1H), 7.24 (s, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 22.5, 34.4, 47.9, 67.8, 112.2, 114.8, 141.1, 143.5, 148.8, 157.1; **MS** (ESI) m/z 250 [M+H]⁺; **HRMS** (ESI, m/z): calcd for C₁₂H₁₆N₃OS [M+H]⁺ 250.10141, found 250.10078.

6-methyl-4-(4-methylpiperidin-1-yl)benzo[*c*][1,2,5]thiadiazole (3j)




Yellow solid, 91 mg, 74%, R_f = 0.44 (EtOAC/Hexane, 05:95); **MP** 165–167°C; **IR** (KBr) 685, 1093, 1200, 1275, 1533, 1658, 2884, 2979 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 0.95 (d, *J* = 6.1 Hz, 3H), 1.41–1.53 (m, 3H), 1.70–1.76 (m, 2H), 2.37 (d, *J* = 1.1 Hz, 3H), 2.72 (dd, *J* = 16.8, 7.1 Hz, 2H), 4.03–4.09 (m, 2H), 6.48 (d, *J* = 1.1 Hz, 1H), 7.18–7.20 (m, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 22.0, 22.5, 31.0, 34.3, 51.0, 111.9, 114.6, 141.2, 144.2, 148.9, 157.1; **MS** (ESI) m/z 248 [M+H]⁺; **HRMS** (ESI, m/z): calcd for C₁₃H₁₈N₃S [M+H]⁺ 248.12214, found 248.12199.

6-methyl-4-(piperidin-1-yl)benzo[c][1,2,5]thiadiazole (3k)




Yellow solid, 80 mg, 68%, $R_f = 0.47$ (EtOAC/Hexane, 05:95); **MP** 142–144°C; IR (KBr) 2933, 2860, 1632, 1533, 1454, 1266, 1102, 817 cm⁻¹; **¹H NMR** (300 MHz, CDCl₃) δ 1.60 (dt, *J* = 10.7, 5.5 Hz, 2H), 1.77 (dd, *J* = 10.5, 5.2 Hz, 4H), 2.38 (s, 3H), 3.35–3.40 (m, 4H), 6.49 (s, 1H), 7.20 (dd, *J* = 5.1, 0.9 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 22.5, 24.6, 26.0, 51.7, 111.9, 114.5, 141.2, 144.4, 148.9, 157.1; **MS** (ESI) m/z 234 [M+H]⁺; **HRMS** (ESI, m/z): calcd for C₁₂H₁₆N₃S [M+H]⁺ 234.11852, found 234.11747.

6-methyl-4-(pyrrolidin-1-yl)benzo[c][1,2,5]thiadiazole (3l)




Yellow solid, 80 mg, 73%, $R_f = 0.62$ (EtOAC/Hexane, 05:95); **MP** 137–139°C; IR (KBr) 809, 1103, 1264, 1458, 1507, 1634, 2929, 2964 cm⁻¹; **¹H NMR** (300 MHz, CDCl₃) δ 1.99–2.10 (m, 4H), 2.43 (s, 3H), 3.77–3.86 (t, *J* = 6.5 Hz, 4H), 6.07 (s, 1H), 7.00 (s, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 22.4, 25.6, 50.1, 106.6, 140.3, 142.1, 147.5, 157.6; **MS** (ESI) m/z 220 [M+H]⁺; **HRMS** (ESI, m/z): calcd for C₁₁H₁₄N₃S [M+H]⁺ 220.10287, found 220.10172.

1-(7-methylbenzo[*c*][1,2,5]thiadiazol-4-yl)piperidin-4-ol (3m)




Yellow solid, 93 mg, 75%, R_f = 0.45(EtOAc/Hexane, 1:1); **MP** 166–168°C; **IR** (KBr) 716, 1047, 1261, 1380, 1463, 2857, 2926 cm^{-1} ; **$^1\text{H NMR}$** (500 MHz, CDCl_3) δ 1.76–1.84 (m, 2H), 2.02–2.11 (m, 2H), 2.56 (d, J = 1.0 Hz, 3H), 3.06–3.16 (m, 2H), 3.77–3.91 (m, 3H), 6.63 (d, J = 7.5 Hz, 1H), 7.15 (dd, J = 7.5, 1.1 Hz, 1H); **$^{13}\text{C NMR}$** (101 MHz, CDCl_3) δ 17.4, 34.4, 48.3, 67.9, 112.5, 123.4, 128.9, 142.6, 150.0, 156.8; **MS** (ESI) m/z 250 [M+H] $^+$ **HRMS** (ESI, m/z): calcd for $\text{C}_{12}\text{H}_{16}\text{N}_3\text{OS}$ [M+H] $^+$ 250.10141, found 250.10074.

4-methyl-7-(4-methylpiperidin-1-yl)benzo[*c*][1,2,5]thiadiazole (3n)




Yellow solid, 89 mg, 72%, R_f = 0.5 (EtOAc/Hexane, 05:95); **MP** 158–160°C; **IR** (KBr) 816, 1097, 1264, 1494, 1561, 1629, 2814, 2968 cm^{-1} ; **$^1\text{H NMR}$** (500 MHz, CDCl_3) δ 0.94 (d, J = 5.2 Hz, 3H), 1.44–1.55 (m, 3H), 1.73 (d, J = 10.8 Hz, 2H), 2.54 (s, 3H), 2.67 (t, J = 11.4 Hz, 2H), 3.97 (d, J = 11.8 Hz, 2H), 6.58 (d, J = 7.4 Hz, 1H), 7.11 (d, J = 7.4 Hz, 1H); **$^{13}\text{C NMR}$** (101 MHz, CDCl_3) δ 16.3, 20.9, 29.9, 33.3, 50.2, 111.1, 121.6, 127.9, 142.2, 149.1, 155.8; **MS** (ESI) m/z 248 [M+H] $^+$ **HRMS** (ESI, m/z): calcd for $\text{C}_{13}\text{H}_{18}\text{N}_3\text{S}$ [M+H] $^+$ 248.13417, found 248.13300.

4-methyl-7-(piperidin-1-yl)benzo[c][1,2,5]thiadiazole (3o)



Yellow solid, 82 mg, 70%, R_f = 0.49 (EtOAC/Hexane, 05:95); **MP** 152–154°C; **IR** (KBr) 814, 1101, 1267, 1447, 1564, 2924, 2972 cm⁻¹; **¹H NMR** (300 MHz, CDCl₃) δ 1.52–1.65 (m, 2H), 1.72–1.82 (m, 4H), 2.55 (s, 3H), 3.23–3.37 (m, 4H), 6.60 (d, *J* = 7.5 Hz, 1H), 7.13 (d, *J* = 7.4 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 16.3, 23.6, 25.0, 50.9, 111.2, 121.9, 127.9, 142.5, 149.1, 155.8; **MS** (ESI) m/z 234 [M+H]⁺**HRMS** (ESI, m/z): calcd for C₁₂H₁₆N₃S [M+H]⁺234.10649, found 234.10624.


1-(6-chlorobenzo[c][1,2,5]thiadiazol-4-yl)piperidin-4-ol (3p)



Yellow solid, 93 mg, 69%, R_f = 0.46 (EtOAC/Hexane, 1:1); **MP** 157–159°C; **IR** (KBr) 664, 935, 1389, 1465, 1536, 1574, 2862, 2935 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 1.77–1.88 (m, 2H), 2.06–2.18 (m, 2H), 3.20–3.34 (m, 2H), 3.94–4.07 (m, 3H), 6.67 (d, *J* = 1.7 Hz, 1H), 7.50 (d, *J* = 1.7 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 34.1, 47.6, 67.5, 111.6, 112.6, 137.7, 144.0, 148.4, 156.4;


MS (ESI) m/z 270 [M+H]⁺ **HRMS** (ESI, m/z): calcd for C₁₁H₁₃ClN₃OS [M+H]⁺ 270.04679, found 270.04591

6-chloro-4-(4-methylpiperidin-1-yl)benzo[c][1,2,5]thiadiazole (3q)



Yellow solid, 81 mg, 61%, **R_f** = 0.42(EtOAC/Hexane, 05:95); **MP** 150–152°C; **IR** (KBr) 627, 851, 1133, 1298, 1573, 2870, 2901 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 0.96 (d, *J* = 6.3 Hz, 3H), 1.32–1.48 (m, 3H), 1.6–1.74 (m, 2H), 3.31–3.51 (m, 13H), 7.27–7.41 (m, 1H), 7.57–7.81 (m, 4H); **¹³C NMR** (101 MHz, CDCl₃) δ 22.3, 30.9, 35.2, 51.9, 114.9, 126.9, 132.9, 141.3, 152.8, 155.4; **MS** (ESI) m/z 268 [M+H]⁺


6-chloro-4-(piperidin-1-yl)benzo[c][1,2,5]thiadiazole (3r)



Yellow solid, 82 mg, 65%, **R_f** = 0.48(EtOAC/Hexane, 05:95); **MP** 155–157°C; **IR** (KBr) 706, 935, 1275, 1534, 1582, 2815, 2968 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 1.64–1.73 (m, 2H), 1.77–1.89 (m, 4H), 3.49–3.60 (m, 4H), 6.64 (s, 1H), 7.48 (s, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 24.5, 25.8,


51.3, 111.2, 112.4, 137.8, 144.8, 148.5, 156.5; **MS** (ESI) m/z 253 [M+H]⁺**HRMS** (ESI, m/z): calcd for C₁₁H₁₂ClN₃S [M+H]⁺253.06390, found 254.06279.

1-(6-fluorobenzo[*c*][1,2,5]thiadiazol-4-yl)piperidin-4-ol (**3s**)



Yellow solid, 88 mg, 70%, **R_f** = 0.52(EtOAC/Hexane, 1:1); **MP** 163–165°C; **IR** (KBr) 697, 848, 1072, 1371, 1497, 1539, 2668, 2941 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 1.75–1.85 (m, 2H), 2.04–2.13 (m, 2H), 3.31–3.44 (m, 2H), 3.75–3.85 (m, 2H), 3.89–3.99 (m, 1H), 7.37 (d, *J* = 12.5, 9.4 Hz, 1H), 7.53 (d, *J* = 9.4, 4.3 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 35.5, 48.9, 68.1, 114.0, 122.8 (d, *J* = 10.1 Hz), 129.1 (d, *J* = 11.4 Hz), 152.4 (d, *J* = 26.0 Hz), 153.38, 154.9; **MS** (ESI) m/z 253 [M+H]⁺**HRMS** (ESI, m/z): calcd for C₁₁H₁₂FN₃OS [M+H]⁺253.07634, found 253.07546.


1-(4,7-dibromobenzo[*c*][1,2,5]thiadiazol-5-yl)piperidin-4-ol (**3t**)



Yellow solid, 69 mg, 35%, **R_f** = 0.46 (EtOAC/Hexane, 1:1); **MP** 162–164°C; **IR** (KBr) 706, 896, 1069, 1476, 1524, 2869, 2945 cm⁻¹; **¹H NMR** (400 MHz, CDCl₃) δ 1.73–1.88 (m, 2H), 2.02–2.11 (m, 2H), 3.38–3.49 (m, 2H), 3.60–3.68 (m, 2H), 3.90–3.99 (m, 1H), 7.81 (s, 1H); **¹³C NMR** (101


MHz, CDCl₃) δ 23.5, 25.7, 51.6, 114.0, 125.9, 131.9, 140.4, 151.8, 154.3; **MS** (ESI) m/z 393 [M+H]⁺**HRMS** (ESI, m/z): calcd for C₁₁H₁₁Br₂N₃OS [M+H]⁺394.07774, found 394.07765.

1-(5,6-dimethylbenzo[c][1,2,5]thiadiazol-4-yl)piperidin-4-ol (3u)



Yellow solid, 72 mg, 55%, R_f = 0.42 (EtOAC/Hexane, 1:1); **MP** 170–172°C; **IR** (KBr) 663, 1069, 1378, 1467, 2870, 2943 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 1.70–1.83 (m, 3H), 1.98–2.10 (m, 2H), 2.43 (s, 3H), 2.44 (s, 3H), 3.37 (d, J = 136.9 Hz, 3H), 3.94 (s, 1H), 7.57 (s, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 14.8, 22.1, 35.7, 49.5, 116.6, 135.3, 141.2, 141.8, 152.1, 155.1; **MS** (ESI) m/z 263 [M+H]⁺**HRMS** (ESI, m/z): calcd for C₁₃H₁₇N₃OS [M+H]⁺263.11706, found 263.11574.

methyl 7-(4-hydroxypiperidin-1-yl)benzo[c][1,2,5]thiadiazole-5-carboxylate (3v)



Yellow solid, 72 mg, 49%, R_f = 0.44 (EtOAC/Hexane, 1:1); **MP** 169–171°C; **IR** (KBr) 1070, 1253, 1289, 1461, 1723, 2860, 2926 cm⁻¹; **¹H NMR** (500 MHz, CDCl₃) δ 1.83–1.89 (m, 2H), 2.15 (dd, J = 13.3, 3.8 Hz, 2H), 3.20–3.30 (m, 2H), 3.98 (s, 3H), 3.99–4.07 (m, J = 14.0, 8.6, 3.4 Hz, 3H), 7.36 (s, 1H), 8.25 (d, J = 0.6 Hz, 1H); **¹³C NMR** (101 MHz, CDCl₃) δ 34.3, 47.9, 52.7, 67.7, 110.8,


115.7, 132.2, 144.1, 151.3, 156.2, 166.9; **MS** (ESI) m/z 294 [M+H]⁺**HRMS** (ESI, m/z): calcd for C₁₃H₁₆N₃O₃S [M+H]⁺294.09124, found 294.09020.

5. References


- [1] H. E. Gottlieb, V. Kotlyar and A. Nudelman, *J. Org. Chem.*, 1997, **62**, 7512–7515.
- [2] (a) J. Wu, G. Lai, Z. Li, Y. Lu, T. Leng, Y. Shen and C. Wang, *Dyes and Pigments*, 2016, **124**, 268–276. (b) R. Agneeswari, V. Tamilavan, M. Song and M. H. Hyun, *J. Mater. Chem. C*, 2014, **2**, 8515–8524. (c) Q. Zhang, J. Zhang, H. Zuo, C. Wang and Y. Shen, *Tetrahedron*, 2016, **72**, 1244–1248. (d) Y. H. Nguyen, B. J. Lampkin, A. Venkatesh, A. Ellern, A. J. Rossini and B. VanVeller, *J. Org. Chem.*, 2018, **83**, *17*, 9850–9857. (e) I. Jeong, S. Chae, A. Yi, J. Kim, H. H. Chun, J. H. Cho, H. J. Kim and H. Suh, *Polymer*, 2017, **109**, *27*, 115–125. (f) Y. Macé, E. Bony, D. Delvaux, A. Pinto, V. Mathieu, R. Kiss, O. Feron, J. Q.-Leclercq and O. Riant, *Med. Chem. Research*, 2015, **24**, *8*, 3143–3156.

6. Copies of ^1H and ^{13}C NMR spectra of 3a to 3y


¹H NMR of **3a** (400 MHz, CDCl₃)




¹³C NMR of **3a** (101 MHz, CDCl₃)




¹H NMR of 3b (500 MHz, CDCl₃)




¹³C NMR of 3b (101 MHz, CDCl₃)




¹H NMR of 3c (400 MHz, CDCl₃)




¹³C NMR of 3c (101 MHz, CDCl₃)




¹H NMR of **3d** (500 MHz, CDCl₃)




¹³C NMR of **3d** (101 MHz, CDCl₃)




¹H NMR of 3e (400 MHz, CDCl₃)




¹³C NMR of 3e (101 MHz, CDCl₃)




¹H NMR of **3f** (400 MHz, CDCl₃)




¹³C NMR of **3f** (101 MHz, CDCl₃)




¹H NMR of 3g(400 MHz, CDCl₃)




¹³C NMR of 3g(101 MHz, CDCl₃)




¹H NMR of **3h**(400 MHz, CDCl₃)




¹³C NMR of **3h**(101 MHz, CDCl₃)




¹H NMR of 3i(500 MHz, CDCl₃)




¹³C NMR of 3i(101 MHz, CDCl₃)




¹H NMR of 3j(400 MHz, CDCl₃)




¹³C NMR of 3j(101 MHz, CDCl₃)




¹H NMR of **3k**(300 MHz, CDCl₃)




¹³C NMR of **3k**(101 MHz, CDCl₃)





¹H NMR of **3I** (300 MHz, CDCl₃)



¹³C NMR of **3I** (101 MHz, CDCl₃)





¹H NMR of **3m** (500 MHz, CDCl₃)




¹³C NMR of 3m (101 MHz, CDCl₃)


—156.82
—150.03
—142.58




¹H NMR of **3n** (500 MHz, CDCl₃)




¹³C NMR of **3n** (101 MHz, CDCl₃)




¹H NMR of **3o** (300 MHz, CDCl₃)




¹³C NMR of **3o** (101 MHz, CDCl₃)




¹H NMR of **3p** (500 MHz, CDCl₃)




¹³C NMR of **3p** (101 MHz, CDCl₃)




¹H NMR of **3q** (400 MHz, CDCl₃)




¹³C NMR of **3q** (101 MHz, CDCl₃)




¹H NMR of **3r** (400 MHz, CDCl₃)




¹³C NMR of **3r** (101 MHz, CDCl₃)




¹H NMR of 3s (400 MHz, CDCl₃)




¹³C NMR of 3s (101 MHz, CDCl₃)




¹H NMR of **3t** (400 MHz, CDCl₃)




¹³C NMR of **3t** (101 MHz, CDCl₃)




¹H NMR of **3u** (500 MHz, CDCl₃)



¹³C NMR of **3u** (101 MHz, CDCl₃)



¹H NMR of **3v** (101 MHz, CDCl₃)



¹³C NMR of **3v** (101 MHz, CDCl₃)

